FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293229969> ?p ?o ?g. }

• W4293229969 abstract "<h3>Background and importance</h3> Graves orbithopathy (OG) is an autoimmune disease and the most common and important manifestation of Graves disease. For patients with moderate-severe disease, initial treatment with corticosteroids is recommended. However, some off-label treatments have been used that have suggested efficacy in various cohort studies and case series, such as tocilizumab. <h3>Aim and objectives</h3> We present the case of a 62-year-old male patient. In 2018, Ophthalmology diagnosed OG according to the criteria of the European Group on Graves Orbithopathy (EUGOGO), with greater proptosis in the left eye compared to the right eye (13–17 mm). He also presented polyarthrosis, hypercholesterolaemia and hypertension. His treatment included carbimazole, losartan, hydrochlorothiazide, loratadine and atorvastatin. Hyperthyroidism was previously treated with tiamazol. <h3>Material and methods</h3> For the evaluation of the disease, measures such as the clinical activity score (CAS) are used. First, the patient was treated with methylprednisolone and radiotherapy without improvement. The Maxillofacial Surgery Service dismissed an intervention considering that there still remained non-invasive treatments with potential benefit. In February 2020, the Ophthalmology Service requested Pharmacy Service off-label use of tocilizumab. The Pharmacy Service carried out bibliographic research and made a report with positive assessment for approval of treatment, supported mainly by a clinical trial. Five 8 mg/kg monthly doses of tocilizumab were administered. Finally, at week 44 (after 32 weeks free of treatment) there arose the possibility of administering two extra doses. <h3>Results</h3> A notable improvement was observed with the first five doses of tocilizumab, achieving a CAS of 2 (low disease activity), with improvement in proptosis (11–15 mm) and good tolerance. A new improvement was achieved after week 44 over the one already shown with the first five doses, and both clinical and analytical parameters (antithyroglobulin levels) improved, with a decrease in the proptosis of both eyes (10–13 mm). The patient reported a good quality of life in the GO-Quality of Life questionnaire. <h3>Conclusion and relevance</h3> The favourable evolution of our patient is consistent with the published data. We only found one clinical trial and some case series, with different dosage of tocilizumab. There still remain doubts about the optimal duration and the possibility of re-treatment with tocilizumab. Collaboration between Ophthalmology and Pharmacy Services is crucial for the rationalisation of therapy with tocilizumab. <h3>References and/or acknowledgements</h3> <h3>Conflict of interest</h3> No conflict of interest" @default.
• W4293229969 created "2022-08-27" @default.
• W4293229969 creator A5005673788 @default.
• W4293229969 creator A5009891265 @default.
• W4293229969 creator A5042159622 @default.
• W4293229969 creator A5085004883 @default.
• W4293229969 creator A5090859843 @default.
• W4293229969 date "2022-03-01" @default.
• W4293229969 modified "2023-09-28" @default.
• W4293229969 title "4CPS-023 Individualisation of treatment with tocilizumab in Graves orbithopathy" @default.
• W4293229969 doi "https://doi.org/10.1136/ejhpharm-2022-eahp.73" @default.
• W4293229969 hasPublicationYear "2022" @default.
• W4293229969 type Work @default.
• W4293229969 citedByCount "1" @default.
• W4293229969 countsByYear W42932299692022 @default.
• W4293229969 crossrefType "proceedings-article" @default.
• W4293229969 hasAuthorship W4293229969A5005673788 @default.
• W4293229969 hasAuthorship W4293229969A5009891265 @default.
• W4293229969 hasAuthorship W4293229969A5042159622 @default.
• W4293229969 hasAuthorship W4293229969A5085004883 @default.
• W4293229969 hasAuthorship W4293229969A5090859843 @default.
• W4293229969 hasBestOaLocation W42932299691 @default.
• W4293229969 hasConcept C104863432 @default.
• W4293229969 hasConcept C126322002 @default.
• W4293229969 hasConcept C187212893 @default.
• W4293229969 hasConcept C2776652619 @default.
• W4293229969 hasConcept C2777178219 @default.
• W4293229969 hasConcept C2777482532 @default.
• W4293229969 hasConcept C2779134260 @default.
• W4293229969 hasConcept C2779442721 @default.
• W4293229969 hasConcept C512399662 @default.
• W4293229969 hasConcept C71924100 @default.
• W4293229969 hasConceptScore W4293229969C104863432 @default.
• W4293229969 hasConceptScore W4293229969C126322002 @default.
• W4293229969 hasConceptScore W4293229969C187212893 @default.
• W4293229969 hasConceptScore W4293229969C2776652619 @default.
• W4293229969 hasConceptScore W4293229969C2777178219 @default.
• W4293229969 hasConceptScore W4293229969C2777482532 @default.
• W4293229969 hasConceptScore W4293229969C2779134260 @default.
• W4293229969 hasConceptScore W4293229969C2779442721 @default.
• W4293229969 hasConceptScore W4293229969C512399662 @default.
• W4293229969 hasConceptScore W4293229969C71924100 @default.
• W4293229969 hasLocation W42932299691 @default.
• W4293229969 hasOpenAccess W4293229969 @default.
• W4293229969 hasPrimaryLocation W42932299691 @default.
• W4293229969 hasRelatedWork W1966618050 @default.
• W4293229969 hasRelatedWork W1972941425 @default.
• W4293229969 hasRelatedWork W2008180595 @default.
• W4293229969 hasRelatedWork W2035998405 @default.
• W4293229969 hasRelatedWork W2052912051 @default.
• W4293229969 hasRelatedWork W2059705985 @default.
• W4293229969 hasRelatedWork W2070274229 @default.
• W4293229969 hasRelatedWork W2780478696 @default.
• W4293229969 hasRelatedWork W2994334483 @default.
• W4293229969 hasRelatedWork W4293229969 @default.
• W4293229969 isParatext "false" @default.
• W4293229969 isRetracted "false" @default.
• W4293229969 workType "article" @default.